M. Stuplich

发表

Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial

Martin Glas, Michael Sabel, Jörg-Christian Tonn, 2019, The Lancet.

Gliomatosis cerebri: no evidence for a separate brain tumor entity

David T. W. Jones, G. Reifenberger, M. Weller, 2016, Acta Neuropathologica.

Tumor growth patterns of MGMT-non-methylated glioblastoma in the randomized GLARIUS trial

V. Rohde, E. Hattingen, C. Belka, 2018, Journal of Cancer Research and Clinical Oncology.

Nimustine (ACNU) Plus Teniposide (VM26) in Recurrent Glioblastoma

T. Hundsberger, D. Kurzwelly, M. Glas, 2009, Oncology.

Intravascular CNS lymphoma: Successful therapy using high-dose methotrexate-based polychemotherapy

H. Urbach, M. Glas, U. Herrlinger, 2012, Experimental Hematology & Oncology.

plasmacytoid dendritic cells secretion of human α P2Y receptor signaling regulates phenotype and IFN

S. Endres, J. Cebon, S. Rothenfusser, 2013 .

P2Y receptor signaling regulates phenotype and IFN-alpha secretion of human plasmacytoid dendritic cells.

S. Endres, J. Cebon, S. Rothenfusser, 2008, Blood.

P 2 Y receptor signaling regulates phenotype and IFN-secretion of human plasmacytoid dendritic cells

S. Endres, J. Cebon, S. Rothenfusser, 2008 .

Richter Syndrome and Brain Involvement: Low-Grade Lymphoma Relapsing as Cerebral High-Grade Lymphoma

M. Glas, K. Mayer, M. Simon, 2011, Acta Haematologica.

Leptomeningeal melanomatosis: Stabilization of disease due to radiation, temozolomide and intrathecal liposomal cytarabine

H. Urbach, M. Glas, U. Herrlinger, 2011, Acta oncologica.

Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial.

H. Urbach, W. Stummer, V. Rohde, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The earlier the better? Bevacizumab in the treatment of recurrent MGMT-non-methylated glioblastoma

H. Vatter, M. Glas, A. Waha, 2016, Journal of Cancer Research and Clinical Oncology.

Late and prolonged pseudoprogression in glioblastoma after treatment with lomustine and temozolomide.

D. Hadizadeh, H. Urbach, K. Langen, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Late Pseudoprogression in Glioblastoma: Diagnostic Value of Dynamic O-(2-[18F]fluoroethyl)-L-Tyrosine PET

R. Fimmers, G. Stoffels, N. Galldiks, 2015, Clinical Cancer Research.

Non-enhancing primary CNS lymphoma

H. Urbach, M. L. Lachenmayer, M. Glas, 2010, Journal of Neuro-Oncology.

Carmustine (BCNU) plus Teniposide (VM26) in Recurrent Malignant Glioma

M. Glas, U. Herrlinger, F. Mack, 2014, Oncology.

Relapse of primary central nervous system lymphoma 13years after high-dose methotrexate-based polychemotherapy

U. Schlegel, M. Glas, U. Herrlinger, 2011, Journal of Clinical Neuroscience.

FLAIR-Only Progression in Bevacizumab-Treated Relapsing Glioblastoma Does Not Predict Short Survival

H. Urbach, M. Glas, M. Simon, 2013, Oncology.

Liposomal cytarabine given concomitantly with radiotherapy in a patient with leptomeningeal metastasis from breast cancer

H. Tschampa, M. Glas, U. Herrlinger, 2008, Journal of Neurology.

Vemurafenib for leptomeningeal melanomatosis.

M. Glas, M. Simon, S. Greschus, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

18F-fluoroethyl-L-tyrosine positron emission tomography for the differential diagnosis of tumefactive multiple sclerosis versus glioma: A case report.

R. Bundschuh, M. Essler, M. Glas, 2016, Oncology letters.

Ifosfamide, Carboplatin and Etoposide in Recurrent Malignant Glioma

J. Steinbach, M. Glas, J. Tichy, 2011, Oncology.

18F-fluoroethyl-L-tyrosine positron emission tomography for the differential diagnosis of tumefactive multiple sclerosis versus glioma: A case report.

R. Bundschuh, M. Essler, M. Glas, 2016, Oncology letters.